KV Pharmaceutical Ther-Rx Ther-Rx
Learn More About
MakenaTM (hydroxyprogesterone caproate injection)
 

Patient Assistance and Access to Makena™

The Makena™ Co-pay Assistance Program

With our Patient Assistance Programs, clinically eligible patients can have affordable access to therapy. Financial assistance is available for clinically eligible insured and uninsured patients upon request.

The Makena Co-pay Assistance Program will reduce co-pay costs for insured patients whose health plan covers Makena™. Patients with a household income of up to $120,000* will pay between $0 and $20 per injection for Makena. Since there are no income caps, patients with a household income greater than $120,000 are also eligible for co-pay assistance.

The Makena Patient Assistance Program supports uninsured patients by offering the drug at no cost or reduced cost. Patients who are uninsured and have an annual household income less than $60,000 will receive Makena at no out-of-pocket cost.

Below is an overview of assistance provided through the program:

Coverage Income Level Copay/Financial Assistance†
Uninsured Up to $60,000 Receive Makena at no cost
Uninsured Above $60,000 Receive Makena at cost equivalent to what insured patients pay out-of-pocket under the Makena copay assistance program
Insured Up to $120,000
(represents 85 percent of household incomes based on 2009 census data) 		Copay of $0-$20 per injection for Makena
Insured Above $120,000
(represents 15 percent of household incomes based on 2009 census data) 		Copay of $40-$80 per injection for Makena
* This encompasses 85% of US household incomes. Source: 2009 US Census Data.
†Gross annual household income and insurance coverage are factors that determine the level of copay or financial assistance a patient is eligible for. There are additional eligibility requirements (i.e. have a Makena prescription, etc.) and these can be discussed on patient-by-patient basis with a representative from the Makena Care Connection, a program designed to help ensure access to Makena.